Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
Paul E, Konidaris G, Cope S, Chen CI, Keeping S, Xu Y, Atsou K, Ayers D, Guyot P, Sasane M, Mojebi A, Kuznik A.
Paul E, et al. Among authors: kuznik a.
J Manag Care Spec Pharm. 2021 Nov;27(11):1513-1525. doi: 10.18553/jmcp.2021.21164. Epub 2021 Aug 5.
J Manag Care Spec Pharm. 2021.
PMID: 34351214
Free PMC article.
METHODS: A "partitioned survival" framework was used to assess the cost-effectiveness of cemiplimab vs pembrolizumab. ...RESULTS: In the base case, cemiplimab resulted in an incremental gain of 3.44 life-years (discounted) and incremental cost-effectiveness ratio (ICER) of …
METHODS: A "partitioned survival" framework was used to assess the cost-effectiveness of cemiplimab vs pembrolizumab. ...RESULTS: In …